Report cover image

Global Injectable HIV Treatment Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 190 Pages
SKU # APRC20279672

Description

Summary

According to APO Research, the global Injectable HIV Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Injectable HIV Treatment market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Injectable HIV Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Injectable HIV Treatment market include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Injectable HIV Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Injectable HIV Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Injectable HIV Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Injectable HIV Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Injectable HIV Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Injectable HIV Treatment sales, projected growth trends, production technology, application and end-user industry.

Injectable HIV Treatment Segment by Company

Theratechnologies
ViiV Healthcare
Gilead Sciences
Janssen Pharmaceuticals
Injectable HIV Treatment Segment by Type

Cabotegravir
Lenacapavir
Rilpivirine
Ibalizumab
Other
Injectable HIV Treatment Segment by Application

Pre-Exposure Prophylaxis
HIV Treatment
Injectable HIV Treatment Segment by Region

North America

United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Injectable HIV Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Injectable HIV Treatment market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Injectable HIV Treatment significant trends, drivers, influence factors in global and regions.
6. To analyze Injectable HIV Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable HIV Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Injectable HIV Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable HIV Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Injectable HIV Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Injectable HIV Treatment industry.
Chapter 3: Detailed analysis of Injectable HIV Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Injectable HIV Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Injectable HIV Treatment in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Injectable HIV Treatment Sales Value (2020-2031)
1.2.2 Global Injectable HIV Treatment Sales Volume (2020-2031)
1.2.3 Global Injectable HIV Treatment Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Injectable HIV Treatment Market Dynamics
2.1 Injectable HIV Treatment Industry Trends
2.2 Injectable HIV Treatment Industry Drivers
2.3 Injectable HIV Treatment Industry Opportunities and Challenges
2.4 Injectable HIV Treatment Industry Restraints
3 Injectable HIV Treatment Market by Company
3.1 Global Injectable HIV Treatment Company Revenue Ranking in 2024
3.2 Global Injectable HIV Treatment Revenue by Company (2020-2025)
3.3 Global Injectable HIV Treatment Sales Volume by Company (2020-2025)
3.4 Global Injectable HIV Treatment Average Price by Company (2020-2025)
3.5 Global Injectable HIV Treatment Company Ranking (2023-2025)
3.6 Global Injectable HIV Treatment Company Manufacturing Base and Headquarters
3.7 Global Injectable HIV Treatment Company Product Type and Application
3.8 Global Injectable HIV Treatment Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Injectable HIV Treatment Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Injectable HIV Treatment Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Injectable HIV Treatment Market by Type
4.1 Injectable HIV Treatment Type Introduction
4.1.1 Cabotegravir
4.1.2 Lenacapavir
4.1.3 Rilpivirine
4.1.4 Ibalizumab
4.1.5 Other
4.2 Global Injectable HIV Treatment Sales Volume by Type
4.2.1 Global Injectable HIV Treatment Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Injectable HIV Treatment Sales Volume by Type (2020-2031)
4.2.3 Global Injectable HIV Treatment Sales Volume Share by Type (2020-2031)
4.3 Global Injectable HIV Treatment Sales Value by Type
4.3.1 Global Injectable HIV Treatment Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Injectable HIV Treatment Sales Value by Type (2020-2031)
4.3.3 Global Injectable HIV Treatment Sales Value Share by Type (2020-2031)
5 Injectable HIV Treatment Market by Application
5.1 Injectable HIV Treatment Application Introduction
5.1.1 Pre-Exposure Prophylaxis
5.1.2 HIV Treatment
5.2 Global Injectable HIV Treatment Sales Volume by Application
5.2.1 Global Injectable HIV Treatment Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Injectable HIV Treatment Sales Volume by Application (2020-2031)
5.2.3 Global Injectable HIV Treatment Sales Volume Share by Application (2020-2031)
5.3 Global Injectable HIV Treatment Sales Value by Application
5.3.1 Global Injectable HIV Treatment Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Injectable HIV Treatment Sales Value by Application (2020-2031)
5.3.3 Global Injectable HIV Treatment Sales Value Share by Application (2020-2031)
6 Injectable HIV Treatment Regional Sales and Value Analysis
6.1 Global Injectable HIV Treatment Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Injectable HIV Treatment Sales by Region (2020-2031)
6.2.1 Global Injectable HIV Treatment Sales by Region: 2020-2025
6.2.2 Global Injectable HIV Treatment Sales by Region (2026-2031)
6.3 Global Injectable HIV Treatment Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Injectable HIV Treatment Sales Value by Region (2020-2031)
6.4.1 Global Injectable HIV Treatment Sales Value by Region: 2020-2025
6.4.2 Global Injectable HIV Treatment Sales Value by Region (2026-2031)
6.5 Global Injectable HIV Treatment Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Injectable HIV Treatment Sales Value (2020-2031)
6.6.2 North America Injectable HIV Treatment Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Injectable HIV Treatment Sales Value (2020-2031)
6.7.2 Europe Injectable HIV Treatment Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Injectable HIV Treatment Sales Value (2020-2031)
6.8.2 Asia-Pacific Injectable HIV Treatment Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Injectable HIV Treatment Sales Value (2020-2031)
6.9.2 South America Injectable HIV Treatment Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Injectable HIV Treatment Sales Value (2020-2031)
6.10.2 Middle East & Africa Injectable HIV Treatment Sales Value Share by Country, 2024 VS 2031
7 Injectable HIV Treatment Country-level Sales and Value Analysis
7.1 Global Injectable HIV Treatment Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Injectable HIV Treatment Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Injectable HIV Treatment Sales by Country (2020-2031)
7.3.1 Global Injectable HIV Treatment Sales by Country (2020-2025)
7.3.2 Global Injectable HIV Treatment Sales by Country (2026-2031)
7.4 Global Injectable HIV Treatment Sales Value by Country (2020-2031)
7.4.1 Global Injectable HIV Treatment Sales Value by Country (2020-2025)
7.4.2 Global Injectable HIV Treatment Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.5.2 USA Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.6.2 Canada Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.8.2 Germany Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.9.2 France Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.9.3 France Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.11.2 Italy Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.12.2 Spain Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.13.2 Russia Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.16.2 China Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.16.3 China Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.17.2 Japan Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.19.2 India Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.19.3 India Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.20.2 Australia Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.24.2 Chile Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.26.2 Peru Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.28.2 Israel Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.29.2 UAE Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.31.2 Iran Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Injectable HIV Treatment Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Injectable HIV Treatment Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Injectable HIV Treatment Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Theratechnologies
8.1.1 Theratechnologies Comapny Information
8.1.2 Theratechnologies Business Overview
8.1.3 Theratechnologies Injectable HIV Treatment Sales, Value and Gross Margin (2020-2025)
8.1.4 Theratechnologies Injectable HIV Treatment Product Portfolio
8.1.5 Theratechnologies Recent Developments
8.2 ViiV Healthcare
8.2.1 ViiV Healthcare Comapny Information
8.2.2 ViiV Healthcare Business Overview
8.2.3 ViiV Healthcare Injectable HIV Treatment Sales, Value and Gross Margin (2020-2025)
8.2.4 ViiV Healthcare Injectable HIV Treatment Product Portfolio
8.2.5 ViiV Healthcare Recent Developments
8.3 Gilead Sciences
8.3.1 Gilead Sciences Comapny Information
8.3.2 Gilead Sciences Business Overview
8.3.3 Gilead Sciences Injectable HIV Treatment Sales, Value and Gross Margin (2020-2025)
8.3.4 Gilead Sciences Injectable HIV Treatment Product Portfolio
8.3.5 Gilead Sciences Recent Developments
8.4 Janssen Pharmaceuticals
8.4.1 Janssen Pharmaceuticals Comapny Information
8.4.2 Janssen Pharmaceuticals Business Overview
8.4.3 Janssen Pharmaceuticals Injectable HIV Treatment Sales, Value and Gross Margin (2020-2025)
8.4.4 Janssen Pharmaceuticals Injectable HIV Treatment Product Portfolio
8.4.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Injectable HIV Treatment Value Chain Analysis
9.1.1 Injectable HIV Treatment Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Injectable HIV Treatment Sales Mode & Process
9.2 Injectable HIV Treatment Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Injectable HIV Treatment Distributors
9.2.3 Injectable HIV Treatment Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.